NCT06635226

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

A Randomized, Double-blinded, Placebo-controlled, Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administrations of ID110521156 in Healthy Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of ID110521156 in healthy adult subjects.

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	ID110521156	ID110521156 capsules taken orally once daily
DRUG	Placebo of 110521156	ID110521156 placebo capsules taken orally once daily

Timeline

• Start date: 2024-11-13
• Primary completion: 2025-06-19
• Completion: 2025-06-19
• First posted: 2024-10-10
• Last updated: 2024-12-24

Locations

1 site across 1 country: South Korea